Cancer Imaging最新文献

{"title":"Optimisation of low and ultra-low dose scanning protocols for ultra-extended field of view PET in a real-world clinical setting.","authors":"Johanna Ingbritsen, Jason Callahan, Hugh Morgan, Melissa Munro, Robert E Ware, Rodney J Hicks","doi":"10.1186/s40644-025-00823-x","DOIUrl":"10.1186/s40644-025-00823-x","url":null,"abstract":"<p><p>True total-body and extended axial field-of-view (AFOV) PET/CT with 1m or more of body coverage are now commercially available and dramatically increase system sensitivity over conventional AFOV PET/CT. The Siemens Biograph Vision Quadra (Quadra), with an AFOV of 106cm, potentially allows use of significantly lower administered radiopharmaceuticals as well as reduced scan times. The aim of this study was to optimise acquisition protocols for routine clinical imaging with FDG on the Quadra the prioritisation of reduced activity given physical infrastructure constraints in our facility. Low-dose (1 MBq/kg) and ultra-low dose (0.5 MBq/g) cohorts, each of 20 patients were scanned in a single bed position for 10 and 15 min respectively with list-mode data acquisition. These data were then reconstructed simulating progressively shorter acquisition times down to 30 s and 1 min, respectively and then reviewed by 2 experienced PET readers who selected the shortest optimal and minimal acquisition durations based on personal preferences. Quantitative analysis was also performed of image noise to assess how this correlated with qualitative preferences. At the consensus minimum acquisition durations at both dosing levels, the coefficient of variance in the liver as a measure of image noise was 10% or less and there was minimal reduction in this measure between the optimal and longest acquisition durations. These data support the reduction in both administered activity and scan acquisition times for routine clinical FDG PET/CT on the Quadra providing efficient workflows and low radiation doses to staff and patients, while achieving high quality images.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"7"},"PeriodicalIF":3.5,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11780987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical evaluation and preliminary clinical study of ⁶⁸Ga-NODAGA-NM-01 for PET imaging of PD-L1 expression.","authors":"Lingzhou Zhao, Jiali Gong, Sisi Liao, Wenhua Huang, Jinhua Zhao, Yan Xing","doi":"10.1186/s40644-025-00826-8","DOIUrl":"10.1186/s40644-025-00826-8","url":null,"abstract":"<p><strong>Background: </strong>Programmed cell death 1/programmed death ligand-1 (PD-L1)-based immune checkpoint blockade is an effective treatment approach for non-small-cell lung cancer (NSCLC). However, immunohistochemistry does not accurately or dynamically reflect PD-L1 expression owing to its spatiotemporal heterogeneity. Herein, we assessed the feasibility of using a ⁶⁸Ga-labeled anti-PD-L1 nanobody, ⁶⁸Ga-NODAGA-NM-01, for PET imaging of PD-L1.</p><p><strong>Methods: </strong>Micro-PET/CT and biodistribution studies were performed on PD-L1-positive and -negative tumor-bearing mice. Additionally, a preliminary clinical study was performed on two patients with NSCLC. NM-01 was radiolabeled with ⁶⁸Ga without further purification under mild conditions.</p><p><strong>Results: </strong>⁶⁸Ga-NODAGA-NM-01 exhibited radiochemical purity (> 98%), high stability in vitro, and rapid blood clearance in vivo. Specific accumulation of ⁶⁸Ga-NODAGA-NM-01 was observed in PD-L1-positive tumor-bearing mice, with a good tumor-to-background ratio 0.5h post-injection. Furthermore, ⁶⁸Ga-NODAGA-NM-01 PET/CT imaging was found to be safe with no adverse events and distinct uptake in primary and metastatic lesions of the PD-L1-positive patient, with a higher maximal standardized uptake value than that in lesions of the PD-L1-negative patient 1h post-injection.</p><p><strong>Conclusions: </strong>⁶⁸Ga-NODAGA-NM-01 can be prepared using a simple method under mild conditions and reflect PD-L1 expression in primary and metastatic lesions. However, our findings need to be confirmed in a large cohort.</p><p><strong>Trial registration: </strong>NCT02978196. Registered February 15, 2018.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"6"},"PeriodicalIF":3.5,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11771120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143051583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of deep learning and radiomic signatures for overall survival prediction in recurrent high-grade glioma treated with immunotherapy.","authors":"Qi Wan, Clifford Lindsay, Chenxi Zhang, Jisoo Kim, Xin Chen, Jing Li, Raymond Y Huang, David A Reardon, Geoffrey S Young, Lei Qin","doi":"10.1186/s40644-024-00818-0","DOIUrl":"10.1186/s40644-024-00818-0","url":null,"abstract":"<p><strong>Background: </strong>Radiomic analysis of quantitative features extracted from segmented medical images can be used for predictive modeling of prognosis in brain tumor patients. Manual segmentation of the tumor components is time-consuming and poses significant reproducibility issues. We compare the prediction of overall survival (OS) in recurrent high-grade glioma(HGG) patients undergoing immunotherapy, using deep learning (DL) classification networks along with radiomic signatures derived from manual and convolutional neural networks (CNN) automated segmentation.</p><p><strong>Materials and methods: </strong>We retrospectively retrieved 154 cases of recurrent HGG from multiple centers. Tumor segmentation was performed by expert radiologists and a convolutional neural network (CNN). From the segmented tumors, 2553 radiomic features were extracted for each case. A robust feature subset was selected using intraclass correlation coefficient analysis between manual and automated segmentations. The data was divided into a 9:1 ratio and validated through ten-fold cross-validation and tested on a rotating test set. Features selection was done by the Kruskal-Wallis test. The Radiomics-based OS predictions, generated using Support Vector Machine (SVM), were compared between the two segmentation approaches and against OS prediction by the CNN model adapted for classification. Model efficacy was evaluated using the area under the receiver operating characteristic curve (AUC).</p><p><strong>Results: </strong>The clinical model AUC for OS prediction was 0.640 ± 0.013 (mean ± 95% confidence interval) in the training set and 0.610 ± 0.131 in the test set. The radiomics prediction of OS based on manual segmentation outperformed automatic segmentation (AUC of 0.662 ± 0.122 vs. 0.471 ± 0.086, respectively) in the test set. Robust features improved the performance of manual segmentation to AUC of 0.700 ± 0.102, of automated segmentation to 0.554 ± 0.085. The CNN prognosis model demonstrated promising results, with an average AUC of 0.755 ± 0.071 for training sets and 0.700 ± 0.101 for the test set.</p><p><strong>Conclusion: </strong>Manual segmentation-derived radiomic features outperformed automated segmentation-derived features for predicting OS in recurrent high-grade glioma patients undergoing immunotherapy. The end-to-end CNN prognosis model performed similarly to radiomics modeling using manual-segmentation-derived features without the need for segmentation. The potential time-saving must be weighed against the lower interpretability of end-to-end black box modeling.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"5"},"PeriodicalIF":3.5,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11752626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-modal radiomics ultrasound model to diagnose cervical lymph node metastases of differentiated thyroid carcinoma: a two-center study.","authors":"Jiajia Tang, Yan Tian, Jiaojiao Ma, Xuehua Xi, Liangkai Wang, Zhe Sun, Xinyi Liu, Xuejiao Yu, Bo Zhang","doi":"10.1186/s40644-025-00825-9","DOIUrl":"10.1186/s40644-025-00825-9","url":null,"abstract":"<p><strong>Objectives: </strong>To establish and validate a dual-modal radiomics nomogram from grayscale ultrasound and color doppler flow imaging (CDFI) of cervical lymph nodes (LNs), aiming to improve the diagnostic accuracy of metastatic LNs in differentiated thyroid carcinoma (DTC).</p><p><strong>Methods: </strong>DTC patients with suspected cervical LNs in two medical centers were retrospectively enrolled. Pathological results were set as gold standard. We extracted radiomic characteristics from grayscale ultrasound and CDFI images, then applied lasso (least absolute shrinkage and selection operator) regression analysis to analyze radiomics features and calculate the rad-score. A nomogram based on rad-score, clinical data, and ultrasound signs was developed. The performance of the model was evaluated using AUC and calibration curve. We also assessed the model's diagnostic ability in European Thyroid Association (ETA) indeterminate LNs.</p><p><strong>Results: </strong>377 DTC patients and 726 LNs were enrolled. 37 radiomics features were determined and calculated as rad-score. The dual-modal radiomics model showed good calibration capabilities. The radiomics model displayed higher diagnostic ability than the traditional ultrasound model in the training set [0.871 (95% CI: 0.839-0.904) vs. 0.848 (95% CI: 0.812-0.884), p<0.01], internal test set [0.804 (95% CI: 0.741-0.867) vs. 0.803 (95% CI: 0.74-0.866), p = 0.696], and external validation cohort [0.939 (95% CI: 0.893-0.984) vs. 0.921 (95% CI: 0.857-0.985), p = 0.026]. The radiomics model could also significantly improve the detection rate of metastatic LNs in the ETA indeterminate LN category.</p><p><strong>Conclusions: </strong>The dual-modal radiomics nomogram can improve the diagnostic accuracy of metastatic LNs of DTC, especially for LNs in ETA indeterminate classification.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"4"},"PeriodicalIF":3.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of EGFR-TKIs and ICIs treatment stratification in non-small cell lung cancer using an encrypted multidimensional radiomics approach.","authors":"Xingping Zhang, Xingting Qiu, Yue Zhang, Qingwen Lai, Yanchun Zhang, Guijuan Zhang","doi":"10.1186/s40644-025-00824-w","DOIUrl":"10.1186/s40644-025-00824-w","url":null,"abstract":"<p><strong>Background: </strong>Radiomics holds great potential for the noninvasive evaluation of EGFR-TKIs and ICIs responses, but data privacy and model robustness challenges limit its current efficacy and safety. This study aims to develop and validate an encrypted multidimensional radiomics approach to enhance the stratification and analysis of therapeutic responses.</p><p><strong>Materials and methods: </strong>This multicenter study incorporated various data types from 506 NSCLC patients, which underwent preprocessing through anonymization methods and were securely encrypted using the AES-CBC algorithm. We developed one clinical model and three radiomics models based on clinical factors and radiomics scores (RadScore) of three distinct regions to evaluate treatment response. Additionally, an integrated radiomics-clinical model was created by combining clinical factors with RadScore. The study also explored the association between different EGFR mutations and PD-1/PD-L1 expression in radiomics biomarkers.</p><p><strong>Findings: </strong>The radiomics-clinical model demonstrated high performance, with AUC values as follows: EGFR (0.884), 19Del (0.894), L858R (0.881), T790M (0.900), and PD-1/PD-L1 expression (0.893) in the test set. This model outperformed both clinical and single radiomics models. Decision curve analysis further supported its superior clinical utility. Additionally, our findings suggest that the efficacy of EGFR-TKIs and ICIs therapy may not depend on detecting a singular tumor feature or cell type.</p><p><strong>Conclusion: </strong>The proposed method effectively balances the level of evidence with privacy protection, enhancing the study's validity and security. Therefore, radiomics biomarkers are expected to complement molecular biology analyses and guide therapeutic strategies for EGFR-TKIs, ICIs, and their combinations.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"3"},"PeriodicalIF":3.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-Prostate-Specific Membrane Antigen PET/CT imaging for potentially resectable pancreatic cancer (PANSCAN-2): a phase I/II study.","authors":"Jisce R Puik, Thomas T Poels, Gerrit K J Hooijer, Matthijs C F Cysouw, Joanne Verheij, Johanna W Wilmink, Elisa Giovannetti, Geert Kazemier, Arantza Farina Sarasqueta, Daniela E Oprea-Lager, Rutger-Jan Swijnenburg","doi":"10.1186/s40644-025-00822-y","DOIUrl":"10.1186/s40644-025-00822-y","url":null,"abstract":"<p><strong>Background: </strong>Current diagnostic imaging modalities have limited ability to differentiate between malignant and benign pancreaticobiliary disease, and lack accuracy in detecting lymph node metastases. ¹⁸F-Prostate-Specific Membrane Antigen (PSMA) PET/CT is an imaging modality used for staging of prostate cancer, but has incidentally also identified PSMA-avid pancreatic lesions, histologically characterized as pancreatic ductal adenocarcinoma (PDAC). This phase I/II study aimed to assess the feasibility of ¹⁸F-PSMA PET/CT to detect PDAC.</p><p><strong>Methods: </strong>Seventeen patients with clinically resectable PDAC underwent ¹⁸F-PSMA PET/CT prior to surgical resection. Images were analyzed both visually and (semi)quantitatively by deriving the maximum standardized uptake value (SUV_max) and tumor-to-background ratio (TBR). TBR was defined as the ratio between SUV_max of the primary tumor divided by SUV_max of the aortic blood pool. Finally, tracer uptake on PET was correlated to tissue expression of PSMA in surgical specimens.</p><p><strong>Results: </strong>Out of 17 PSMA PET/CT scans, 13 scans demonstrated positive PSMA tracer uptake, with a mean SUV_max of 5.0 ± 1.3. The suspected primary tumor was detectable (TBR ≥ 2) with a mean TBR of 3.3 ± 1.3. For histologically confirmed PDAC, mean SUV_max and mean TBR were 4.9 ± 1.2 and 3.3 ± 1.5, respectively. Although eight patients had histologically confirmed regional lymph node metastases and two patients had distant metastases, none of these metastases demonstrated ¹⁸F-PSMA uptake. There was no correlation between ¹⁸F-PSMA PET/CT SUV_max and tissue expression of PSMA in surgical specimens.</p><p><strong>Conclusions: </strong>¹⁸F-PSMA PET/CT was able to detect several pancreaticobiliary cancers, including PDAC. However, uptake was generally low, not specific to PDAC and no tracer uptake was observed in lymph node or distant metastases. The added value of PSMA PET in this setting appears to be limited.</p><p><strong>Trial registration: </strong>The trial is registered as PANSCAN-2 in the European Clinical Trials Database (EudraCT number: 2020-002185-14).</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"2"},"PeriodicalIF":3.5,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound super-resolution imaging for non-invasive assessment of microvessel in prostate lesion.","authors":"Xin Huang, Huarong Ye, Yugang Hu, Yumeng Lei, Yi Tian, Xingyue Huang, Jun Zhang, Yao Zhang, Bin Gui, Qianhui Liu, Ge Zhang, Qing Deng","doi":"10.1186/s40644-024-00819-z","DOIUrl":"https://doi.org/10.1186/s40644-024-00819-z","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) is the leading cause of cancer-related morbidity and mortality in men worldwide. An early and accurate diagnosis is crucial for effective treatment and prognosis. Traditional invasive procedures such as image-guided prostate biopsy often cause discomfort and complications, deterring some patients from undergoing these necessary tests. This study aimed to explore the feasibility and clinical value of using ultrasound super-resolution imaging (US SRI) for non-invasively assessing the microvessel characteristics of prostate lesion.</p><p><strong>Methods: </strong>This study included 127 patients with prostate lesion who presented at Renmin Hospital of Wuhan University between November 2023 and June 2024 were included in this study. All the patients underwent transrectal US (TRUS), contrast-enhanced US (CEUS), and US SRI. CEUS parameters of time-intensity curve (TIC): arrival time (AT), rising time (RT), time to peak (TTP), peak intensity (PKI), falling time (FT), mean transit time (MTT), ascending slope (AS), descending slope (DS), D/A slope ratio (SR), and area under the TIC (AUC). US SRI parameters: microvessel density (MVD), microvessel diameter (D), microvessel velocity (V), microvessel tortuosity (T), and fractal number (FN), were analyzed and compared between prostate benign and malignant lesion.</p><p><strong>Results: </strong>The tumor markers of prostate in the malignant group were all higher than those in the benign group, and the differences were statistically significant (P < 0.001). The TIC parameters of CEUS revealed that the PKI, AS, DS, and AUC were significantly higher in the malignant group than in the benign group (P < 0.001), whereas the RT, TTP and FT in the malignant group were significantly lower (P < 0.001). Malignant lesion exhibited significantly higher MVD, larger D, faster V, greater T, and more complex FN than benign lesion (P < 0.001).</p><p><strong>Conclusions: </strong>US SRI is a promising non-invasive imaging modality that can provide detailed microvessel characteristics of prostate lesion, offering an advancement in the differential diagnosis for prostate lesion. And, US SRI may be a valuable tool in clinical practice with its ability to display and quantify microvessel with high precision.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"1"},"PeriodicalIF":3.5,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of Ki-67 expression in gastric gastrointestinal stromal tumors using histogram analysis of monochromatic and iodine images derived from spectral CT.","authors":"Xianwang Liu, Tao Han, Yuzhu Wang, Hong Liu, Juan Deng, Caiqiang Xue, Shenglin Li, Junlin Zhou","doi":"10.1186/s40644-024-00820-6","DOIUrl":"10.1186/s40644-024-00820-6","url":null,"abstract":"<p><strong>Purpose: </strong>To assess and compare the diagnostic efficiency of histogram analysis of monochromatic and iodine images derived from spectral CT in predicting Ki-67 expression in gastric gastrointestinal stromal tumors (gGIST).</p><p><strong>Methods: </strong>Sixty-five patients with gGIST who underwent spectral CT were divided into a low-level Ki-67 expression group (LEG, Ki-67 < 10%, n = 33) and a high-level Ki-67 expression group (HEG, Ki-67 ≥ 10%, n = 32). Conventional CT features were extracted and compared. Histogram parameters were extracted from monochromatic and iodine images, respectively. The diagnostic efficiency of the histogram parameters from monochromatic and iodine images was assessed and compared between the two groups. Spearman's correlation analysis was used to correlate histogram parameters with Ki-67 expression.</p><p><strong>Results: </strong>The HEG was more likely to present with an irregular shape and a larger size than the LEG (all p < 0.05). Regarding histogram parameters, the HEG showed higher maximum, mean, Perc.10, Perc.25, Perc.50, Perc.75, Perc.90, Perc.99, SD, variance, and CV of monochromatic images; higher maximum, Perc.99, and entropy of iodine images, compared with the LEG (all p < 0.003125). ROC analysis showed that significant histogram parameters of monochromatic and iodine images allowed for effective differentiation between LEG and HEG. DeLong's test showed that the diagnostic efficiency of histogram parameters in monochromatic images (Perc.90) was superior to that of iodine images (maximum) (p = 0.010). A positive correlation was observed between the significant histogram parameters and Ki-67 expression (all p < 0.05).</p><p><strong>Conclusion: </strong>Both histogram analysis of monochromatic and iodine images derived from spectral CT can predict Ki-67 expression in gGIST, and the diagnostic efficacy of monochromatic images is superior to iodine images.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"173"},"PeriodicalIF":3.5,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of MGMT promoter methylation status in glioblastoma using deep learning features from multi-sequence MRI of intratumoral and peritumoral regions.","authors":"Xuan Yu, Jing Zhou, Yaping Wu, Yan Bai, Nan Meng, Qingxia Wu, Shuting Jin, Huanhuan Liu, Panlong Li, Meiyun Wang","doi":"10.1186/s40644-024-00817-1","DOIUrl":"10.1186/s40644-024-00817-1","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate the effectiveness of deep learning features derived from multi-sequence magnetic resonance imaging (MRI) in determining the O⁶-methylguanine-DNA methyltransferase (MGMT) promoter methylation status among glioblastoma patients.</p><p><strong>Methods: </strong>Clinical, pathological, and MRI data of 356 glioblastoma patients (251 methylated, 105 unmethylated) were retrospectively examined from the public dataset The Cancer Imaging Archive. Each patient underwent preoperative multi-sequence brain MRI scans, which included T1-weighted imaging (T1WI) and contrast-enhanced T1-weighted imaging (CE-T1WI). Regions of interest (ROIs) were delineated to identify the necrotic tumor core (NCR), enhancing tumor (ET), and peritumoral edema (PED). The ET and NCR regions were categorized as intratumoral ROIs, whereas the PED region was categorized as peritumoral ROIs. Predictive models were developed using the Transformer algorithm based on intratumoral, peritumoral, and combined MRI features. The area under the receiver operating characteristic curve (AUC) was employed to assess predictive performance.</p><p><strong>Results: </strong>The ROI-based models of intratumoral and peritumoral regions, utilizing deep learning algorithms on multi-sequence MRI, were capable of predicting MGMT promoter methylation status in glioblastoma patients. The combined model of intratumoral and peritumoral regions exhibited superior diagnostic performance relative to individual models, achieving an AUC of 0.923 (95% confidence interval [CI]: 0.890 - 0.948) in stratified cross-validation, with sensitivity and specificity of 86.45% and 87.62%, respectively.</p><p><strong>Conclusion: </strong>The deep learning model based on MRI data can effectively distinguish between glioblastoma patients with and without MGMT promoter methylation.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"172"},"PeriodicalIF":3.5,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of metabolic tumor volume on [¹⁸F]FDG PET/CT in addition to the TNM classification system of locally advanced non-small cell lung cancer.","authors":"Alexander Brose, Isabelle Miederer, Jochem König, Eleni Gkika, Jörg Sahlmann, Tanja Schimek-Jasch, Mathias Schreckenberger, Ursula Nestle, Jutta Kappes, Matthias Miederer","doi":"10.1186/s40644-024-00811-7","DOIUrl":"10.1186/s40644-024-00811-7","url":null,"abstract":"<p><strong>Purpose: </strong>Staging of non-small cell lung cancer (NSCLC) is commonly based on [¹⁸F]FDG PET/CT, in particular to exclude distant metastases and guide local therapy approaches like resection and radiotherapy. Although it is hoped that PET/CT will increase the value of primary staging compared to conventional imaging, it is generally limited to the characterization of TNM. The first aim of this study was to evaluate the PET parameter metabolic tumor volume (MTV) above liver background uptake as a prognostic marker in lung cancer. The second aim was to investigate the possibility of incorporating MTV into the TNM classification system for disease prognosis in locally advanced NSCLC treated with chemoradiotherapy.</p><p><strong>Methods: </strong>Retrospective evaluation of 235 patients with histologically proven, locally advanced NSCLC from the multi-centre randomized clinical PETPLAN trial and a clinical cohort from a hospital registry. The PET parameters SUVmax, SULpeak, MTV and TLG above liver background uptake were determined. Kaplan-Meier curves and stratified Cox proportional hazard regression models were used to investigate the prognostic value of PET parameters and TNM along with clinical variables. Subgroup analyses were performed to compare hazard ratios according to TNM, MTV, and the two variables combined.</p><p><strong>Results: </strong>In the multivariable Cox regression analysis, MTV was associated with significantly worse overall survival independent of stage and other prognostic variables. In locally advanced disease stages treated with chemoradiotherapy, higher MTV was significantly associated with worse survival (median 17 vs. 32 months). Using simple cut-off values (45 ml for stage IIIa, 48 ml for stage IIIb, and 105 ml for stage IIIc), MTV was able to further predict differences in survival for stages IIIa-c. The combination of TNM and MTV staging system showed better discrimination for overall survival in locally advanced disease stages, compared to TNM alone.</p><p><strong>Conclusion: </strong>Higher metabolic tumor volume is significantly associated with worse overall survival and combined with TNM staging, it provides more precise information about the disease prognosis in locally advanced NSCLC treated with chemoradiotherapy compared to TNM alone. As a PET parameter with volumetric information, MTV represents a useful addition to TNM.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"171"},"PeriodicalIF":3.5,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11662478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}